2020年11月19日07:00 GMT
Presentations support Calquence efficacy and tolerability with long-term follow-up in mantle cell lymphoma and pooled safety data in chronic lymphocytic leukaemia
Emerging pipeline shows promise with novel targets and mechanisms to treat resistant and aggressive blood cancers
澳门葡京网赌游戏 will present new research aimed at addressing key unmet needs facing patients with blood cancers at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 于2020年12月5日至8日举行.
The Company will present 27 abstracts spanning five medicines and potential new medicines and eight different haematology conditions that demonstrate the Company’s commitment to advancing haematology research and treatments for patients living with haematologic malignancies.
主要数据展示包括:
- 四项试验数据的汇总分析- ELEVATE TN, 提升, ACE-CL-001和15-H-0016 -扩展心血管安全性 Calquence 慢性淋巴细胞白血病(CLL)的单药治疗
- Extended follow-up data from the pivotal Phase II ACE-LY-004 trial that support long-term treatment with Calquence 成人复发或难治性套细胞淋巴瘤(制程)
- 上的数据 Calquence 在CLL患者中联合venetoclax和obinutuzumab或rituximab, showing a safety profile consistent with previous trials with high complete responses and undetectable minimal residual disease rates after a median follow-up of 26.9个月，Ib期ACE-CL-003试验中药物-药物相互作用最小或没有
- First-in-human data from the potential new medicine B-cell maturation antigen (BCMA)-targeted antibody drug conjugate, MEDI2228, 提供复发或难治性多发性骨髓瘤在所有剂量水平下的安全性和有效性数据
- Data showing pre-clinical evidence of overcoming resistance in relapsed or refractory 制程 from the dual BCL2/XL inhibitor, AZD4320, 是什么阻断了BCL2和BCLXL的抗凋亡作用
- 抗诱导共刺激物抗icos单克隆抗体的I期数据, 读出- 570, demonstrating promising early clinical activity in poor-risk refractory and heavily pre-treated patients with angioimmunoblastic T-cell lymphoma
- 罗沙他的多项研究, the first in a new class of medicines evaluating its clinical effectiveness and safety profile in both the dialysis dependent and non-dialysis dependent anaemia of CKD patient populations
- 上的数据 roxadustat assessing efficacy in anaemia secondary to lower-risk myelodysplastic syndrome (MDS) regardless of baseline factors. 大约三分之一的MDS患者会导致急性髓性白血病.1
戴夫Fredrickson, 执行副总裁, 肿瘤事业部, 他说:“澳门葡京赌博游戏今年在ASH的数据继续支持 Calquence 作为一种耐受性良好的治疗方法，对多种血癌具有令人印象深刻的疗效和安全性, 增强医生治疗病人的信心 Calquence 从长远来看. 会议还将探讨数据 Calquence 与常用疗法联合使用, showing potential across a variety of regimens in chronic lymphocytic leukaemia to best suit the unique needs of each patient.”
josore Baselga，肿瘤学研究执行副总裁&D, 他说:“随着澳门葡京赌博游戏在血液学领域的业务迅速扩大, we are focused on identifying novel targets and mechanisms of action that can address the most urgent unmet needs across various haematological malignancies. Our early portfolio at this year’s ASH clearly demonstrates our commitment to following the science in combating treatment-resistant and rare blood cancers.”
澳门葡京网赌游戏在第62届ASH年会和博览会上的主要演讲
Calquence
Calquence acalabrutinib是布鲁顿酪氨酸激酶(BTK)的新一代选择性抑制剂。. Calquence 与BTK共价结合，从而抑制其活性.2,3 在b细胞, BTK信号导致b细胞增殖所需通路的激活, 人口贩卖, 趋化性, 和附着力.2
作为广泛临床发展计划的一部分, 澳门葡京网赌游戏和阿赛特制药目前正在评估 Calquence 在20多个公司赞助的临床试验中. Calquence 正在开发用于治疗多种b细胞血癌，包括CLL, 制程, 弥漫大b细胞淋巴瘤, Waldenstrom macroglobulinaemia, 滤泡淋巴瘤, 以及其他血液恶性肿瘤.
Roxadustat
Roxadustat is a first-in-class oral small molecule hypoxia-inducible-factor prolyl hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increased endogenous production of erythropoietin; improved iron absorption, transport and mobilisation; and downregulation of hepcidin, which helps to overcome the negative impact of inflammation on haemoglobin synthesis and red blood cell production. Roxadustat在中国被批准用于治疗成年CKD患者的贫血, 有透析的，也有不透析的. 在日本, roxadustat被批准用于CKD透析患者的贫血治疗, and a supplemental New Drug Application (NDA) for the treatment of anaemia in CKD patients not on dialysis is under regulatory review. The roxadustat NDA for the treatment of anaemia in CKD in both NDD and DD is under review by the US Food and Drug Administration with a decision expected in Q4 2020. The Marketing Authorisation Application for roxadustat for the treatment of anaemia in CKD in both NDD and DD was filed by Astellas and accepted by the 欧洲an 药物 Agency for review on 21 May 2020. Roxadustat is also in clinical development for anaemia associated with MDS and for chemotherapy-induced anaemia.
澳门葡京网赌游戏和纤维原公司. (FibroGen) are collaborating on the development and commercialisation of roxadustat for the potential treatment of anaemia in the US, 中国以及美洲和澳大利亚/新西兰的其他市场, 以及东南亚. Astellas and FibroGen are collaborating on the development and commercialisation of roxadustat for the potential treatment of anaemia in territories including Japan, 欧洲, 独立国家联合体, 中东和南非.
澳门葡京网赌游戏在血液学
利用其在肿瘤学领域的优势, 澳门葡京网赌游戏已将血液学确立为四个重点肿瘤疾病领域之一. The Company’s haematology franchise includes two medicines approved by the US Food and Drug Administration and a robust global development programme for a broad portfolio of potential blood cancer treatments. Acerta Pharma是澳门葡京网赌游戏的血液学研究和开发部门. 澳门葡京网赌游戏 partners with like-minded science-led companies to advance the discovery and development of therapies to address unmet need.
澳门葡京网赌游戏在肿瘤学
澳门葡京网赌游戏 has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients' lives and the Company's future. 2014年至2020年间有7种新药上市, 还有大量正在开发的小分子和生物制剂, 公司致力于将肿瘤作为澳门葡京网赌游戏专注于肺部的关键增长动力, 卵巢, 乳腺癌和血癌.
通过利用六个科学平台的力量-免疫肿瘤学, 肿瘤驱动因素和耐药性, DNA损伤反应, 抗体药物偶联物, 表观遗传学, 和细胞疗法——并通过支持个性化组合的发展, 澳门葡京网赌游戏的愿景是重新定义癌症治疗，并有一天消除癌症这一死亡原因.
澳门葡京网赌游戏
澳门葡京网赌游戏(LSE/STO/Nasdaq: AZN)是一家全球性制药公司, 以科学为主导的澳门葡京赌博游戏公司，专注于发现, 处方药的开发和商业化, 主要用于治疗肿瘤等三个治疗领域的疾病, 心血管, 肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门葡京网赌游戏 operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 请访问 澳门葡京网赌游戏.com 并在推特上关注公司 @澳门葡京网赌游戏.
联系人
有关联络投资者关系小组的详情，请按此处. 对于“媒体联系人”，单击 在这里.
参考文献
1. 美国癌症协会. 什么是骨髓增生异常综合征? 网上. 2020年10月.
2. Calquence (acalabrutinib)[处方资料]. Wilmington, DE; 澳门葡京网赌游戏 Pharmaceuticals LP; 2019.
3. 吴杰，张敏 & 刘D. Acalabrutinib (ACP-196):选择性第二代BTK抑制剂. [J]血液学. 2016;9(21).
艾德里安·坎普
公司秘书
澳门葡京网赌游戏